A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX? in healthy children
Journal
Vaccine
Journal Volume
20
Journal Issue
23-24
Pages
2942-2949
Date Issued
2002
Author(s)
Lau Y.-L.
Vessey S.J.R.
Chan I.S.F.
Lee T.-L.
Lee C.-Y.
Lin T.-Y.
Lee B.W.
Kwan K.
Kasim S.M.
Chan C.Y.
Kaplan K.M.
Distefano D.J.
Harmon A.L.
Golie A.
Hartzel J.
Xu J.
Li S.
Matthews H.
Sadoff J.C.
Shaw A.
Abstract
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX? [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (?50,000 plaque forming units (PFU), Group A or ?16,000PFU, Group B) or 1 dose of VARILRIX?, (?40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ?5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. ? 2002 Elsevier Science Ltd. All rights reserved.
Subjects
Immunogenicity; Varicella vaccination; Varicella zoster virus
SDGs
Other Subjects
chickenpox vaccine; measles mumps rubella vaccine; mmr; varicella zoster vaccine; chickenpox vaccine; live vaccine; virus antibody; chickenpox; clinical trial; conference paper; controlled clinical trial; controlled study; death; double blind procedure; drug safety; drug tolerability; ecchymosis; enzyme linked immunosorbent assay; erythema; female; human; human experiment; immunogenicity; male; multicenter study; normal human; preschool child; priority journal; randomized controlled trial; rash; side effect; vaccination; Varicella zoster virus; virus titration; article; blood; comparative study; drug tolerance; immunology; infant; safety; Antibodies, Viral; Chickenpox Vaccine; Comparative Study; Double-Blind Method; Drug Tolerance; Enzyme-Linked Immunosorbent Assay; Female; Herpesvirus 3, Human; Human; Infant; Male; Safety; Support, Non-U.S. Gov't; Vaccines, Attenuated; Antibodies, Viral; Double-Blind Method; Drug Tolerance; Enzyme-Linked Immunosorbent Assay; Female; Herpesvirus 3, Human; Humans; Infant; Male; Safety; Vaccines, Attenuated
Type
conference paper